Vanguard Capital Management
NBIX icon

Vanguard Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Vanguard Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$766M Buy
4,545,339
+33,435
+0.7% +$4.96M 0.02% 564
2026
Q1 		$594M Buy
+4,511,904
New +$599M 0.01% 603

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's NBIX Position: Q2 2026 in Review

Vanguard Capital Management increased its Neurocrine Biosciences (NBIX) stake by 0.74% in Q2 2026, buying an estimated $4.96M and bringing the position to 4,545,339 shares worth $766M. The position accounts for 0.02% of the portfolio, ranked #564.

Vanguard Capital Management first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Vanguard Capital Management held 4,545,339 shares of Neurocrine Biosciences worth $766M as of Q2 2026.
  • Vanguard Capital Management bought 33,435 Neurocrine Biosciences shares in Q2 2026, an estimated $4.96M.
  • Neurocrine Biosciences made up 0.02% of Vanguard Capital Management's portfolio in Q2 2026, its #564 holding.
  • Vanguard Capital Management first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.